Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

14
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
14
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

626
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
626

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Blood·2014
Same author

Daratumumab granted breakthrough drug status.

Expert opinion on investigational drugs·2014
Same author

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

International journal of oncology·2014
Same author

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Blood·2014
Same author

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Nature communications·2014
Same author

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Multiple myeloma: a clinical overview.

Kenneth C Anderson

    Oncology (Williston Park, N.Y.)
    |September 5, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Multiple myeloma (MM) is a progressive plasma cell cancer. Advances have doubled survival, but new genetic markers may refine staging and personalize treatment for this incurable hematologic malignancy.

    More Related Videos

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    12.5K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Related Experiment Videos

    Last Updated: Apr 24, 2026

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    6.1K
    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    12.5K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Area of Science:

    • Hematology
    • Oncology
    • Cancer Biology

    Background:

    • Multiple myeloma (MM) is the second most common hematologic malignancy in the US.
    • Older age and obesity are key risk factors for MM.
    • While incurable, MM survival has doubled due to recent treatment advances.

    Purpose of the Study:

    • To review the pathophysiology of multiple myeloma.
    • To discuss current staging systems and emerging prognostic markers.
    • To highlight the impact of tumor-host interactions in MM progression.

    Main Methods:

    • Literature review of MM pathophysiology, risk factors, and treatment.
    • Analysis of current staging systems (Durie-Salmon and ISS).
    • Discussion of emerging cytogenetic markers for prognosis.

    Main Results:

    • MM involves malignant plasma cell proliferation and disruption of the bone marrow microenvironment.
    • Tumor-host interactions drive MM progression, leading to bone lesions, infections, and organ damage.
    • Cytogenetic markers are emerging as crucial prognostic indicators.

    Conclusions:

    • MM remains a complex, incurable malignancy with significant morbidity.
    • Refined staging systems incorporating genetic profiles hold promise for tailored MM treatment strategies.